The Save MEDICARE Act of 2026 aims to improve the Medicare Advantage program by starting in 2028 with several changes to how health plans are paid and monitored. It requires the government to exclude diagnoses from chart reviews when calculating payments to prevent plans from inflating costs based on questionable data. The bill also speeds up audits and appeals to ensure faster resolution of coding disputes and introduces a new penalty system to recover overpayments from plans. Additionally, the law allows states to enforce Medicare rules within their borders and bans financial incentives for doctors based on how they code patient records. Finally, it establishes a mechanism for the Department of Veterans Affairs to recover costs when Medicare Advantage plans cover care that should have been paid for by the VA.
This resolution designates July 2026 as "Plastic Pollution Action Month" to raise awareness about the environmental and health risks associated with plastic waste. The bill recognizes that plastic pollution harms marine life and human health, citing statistics on ocean contamination and the presence of microplastics in the human body. It encourages all individuals in the United States to participate in activities aimed at reducing plastic use and cleaning up litter during the designated month. The measure does not create new laws or regulations but serves to highlight the issue and promote voluntary action.
This resolution honors the life and legacy of the late Senator Lindsey Olin Graham from South Carolina. It formally acknowledges his extensive career in the military, state government, and Congress, noting his service as a Senator and his roles as Chairman of the Judiciary and Budget committees. The Senate expresses its sorrow over his death and requests that this tribute be shared with the House of Representatives and Graham's family.
The Cannabis Administration and Opportunity Act fundamentally changes federal law by removing marijuana from the Controlled Substances Act, effectively decriminalizing it at the federal level and allowing states to regulate their own cannabis markets without federal interference. To manage this new landscape, the bill creates a new federal agency called the Alcohol, Tobacco, and Cannabis Tax and Trade Bureau to oversee licensing, collect taxes, and prevent illicit trade, while also establishing a new Center for Cannabis Products within the FDA to regulate safety and labeling. The legislation includes significant restorative justice measures, such as automatically expunging federal cannabis convictions and prohibiting discrimination against individuals with such records in areas like immigration, security clearances, and access to federal benefits. Additionally, the bill provides billions of dollars in funding to support research into the health effects of cannabis, expand access to financial services for legitimate cannabis businesses, and assist communities and individuals harmed by past prohibition enforcement.
The Protecting Students from Worthless Degrees Act restricts federal funding for college programs that fail to meet specific standards regarding licensure preparation and student earnings. To qualify for federal aid, programs designed to prepare students for licensed professions must ensure graduates can take required exams and obtain certification in the state where they live, while also providing necessary internships or clinical placements. Additionally, the bill introduces a debt-to-earnings test that bars funding for programs where the average student's annual loan payments exceed 8% of their median earnings or where payments exceed 20% of their discretionary income. Institutions offering distance learning courses must also be legally authorized in every state where their students reside, unless participating in a mutual agreement between states.
The Curtailing Executive Overcompensation (CEO) Act imposes a new excise tax on large companies where the highest-paid CEO earns significantly more than the median worker. This tax applies to employers with over $100 million in annual revenue and over $10 million in wages, charging a fee equal to the lesser of 1% of the pay gap or 1% of the company's gross receipts. The law defines the pay gap as the difference between the CEO's average compensation and 50 times the median wage of all employees earning at least $5,000, with thresholds adjusted for inflation after 2027. Companies found to be manipulating their workforce to avoid the tax could face joint liability, and the IRS will issue regulations to prevent such avoidance.
Orlin's Law requires immigration officials to identify detained parents and prioritize family unity by limiting detention when possible. The bill mandates that parents be allowed to make free calls and visits with their children, participate in family court proceedings, and access necessary documents to care for their dependents. It also establishes a new office within U.S. Immigration and Customs Enforcement to coordinate these protections and provides for community-based alternatives to detention. Additionally, the law creates a presumption that parental rights remain intact even if a child is separated from a detained parent and outlines specific steps to facilitate reunification upon removal.
The Stop CHEATERS Act directs the Internal Revenue Service to increase its enforcement efforts against high-income individuals and large corporations by allocating billions of dollars in additional funding for tax audits, criminal investigations, and taxpayer services through fiscal year 2031. A significant portion of this funding is designated for modernizing the IRS's technology and business systems to improve its ability to detect fraud and noncompliance. The legislation also requires the IRS Commissioner to submit regular reports to Congress detailing plans to shift auditing resources toward wealthy taxpayers and analyzing how much unpaid tax is owed by different income groups.
This joint resolution seeks to officially disapprove a specific rule issued by the Centers for Medicare & Medicaid Services regarding the implementation of prior authorization for certain Medicare services. The proposed action would prevent the rule, known as the WISeR Model, from taking effect, thereby stopping the new requirements from being enforced. If passed, the resolution would nullify the regulation and maintain the status quo for the affected healthcare services.
The Work Without Worry Act of 2026 changes how the Social Security Administration evaluates disability for children who receive benefits based on a parent's work record. It allows these children to be considered disabled even if their condition started before age 22 but continued after that age, removing the requirement that they remain disabled continuously until they apply for benefits. Additionally, the bill treats a child's application for benefits as a simultaneous request for their own disability or retirement benefits if they meet specific age and insurance criteria, though they will only receive the higher payment amount. These changes apply to applications filed at least two years after the law is enacted.
This bill, known as the Epstein Files Transparency Act II, strengthens the ability of state attorneys general, district attorneys, and victims to legally challenge the U.S. Attorney General for withholding or redacting records related to the Jeffrey Epstein investigation. It grants these parties the right to sue in federal court to force the release of unredacted documents, including classified materials, while requiring courts to expedite these cases. The legislation clarifies that federal agencies cannot use standard legal privileges to hide relevant evidence and explicitly defines who qualifies as a victim for the purposes of accessing these files. Additionally, it ensures that state and local law enforcement can use the released information in their own investigations without being restricted by federal privacy regulations.
The Cancer Drug Parity Act of 2026 requires group health plans and insurance coverage to treat the cost-sharing for oral cancer medications no less favorably than that for intravenously administered cancer drugs. This rule applies to FDA-approved oral cancer treatments that a treating physician deems medically necessary and clinically appropriate, ensuring that deductibles, copayments, and coinsurance rates are not higher for oral options. The legislation also prohibits plans from making changes that would increase out-of-pocket costs or impose stricter limitations on oral cancer drugs compared to injected ones, while still allowing for standard utilization controls like prior authorization. Additionally, the bill mandates a Government Accountability Office study within two years to assess the impact of these changes on patient costs and access.
